Clinical experience with inhibition of interleukin-6

Rheumatic Disease Clinics of North America

Volumn 30, Issue 2, 2004, Pages 405-415

  Choy, Ernest ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN A; GLUCOCORTICOID; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PREDNISOLONE; PREDNISONE;

CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; HUMAN; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INTERLEUKIN-6; MODELS, ANIMAL; SIGNAL TRANSDUCTION; SYNOVITIS;

EID: 2542477009     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2004.01.008     Document Type: Review

References (45)

1. Pincus T., Callahan L.F., Sale W.G., Brooks A.L., Payne L.E., Vaughn W.K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 27:1984;864-872
2. Pincus T., Callahan L.F. Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol. 19:1992;1051-1057
3. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 359:2002;1173-1177
4. Pincus T. Long-term outcome in rheumatoid arthritis. Br J Rheumatol. 34(Suppl 2):1995;59-73
5. Scott D.L., Symmons D.P., Coulton B.L., Popert A.J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1:1987;1108-1111
6. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4:1990;2860-2867
7. Akira S., Isshiki H., Nakajima T., Kinoshita S., Nishio Y., Natsuka S., et al. Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Found Symp. 167:1992;47-62
8. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1254
9. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 15:1997;797-819
10. Kishimoto T., Tanaka T., Yoshida K., Akira S., Taga T. Cytokine signal transduction through a homo- or heterodimer of gp130. Ann N Y Acad Sci. 766:1995;224-234
11. Bravo J., Heath J.K. Receptor recognition by gp130 cytokines. EMBO J. 19:2000;2399-2411
12. Minami M., Inoue M., Wei S., Takeda K., Matsumoto M., Kishimoto T., et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A. 93:1996;3963-3966
13. Kishimoto T. Signal transduction through homo- or heterodimers of gp130. Stem Cells. 12(Suppl 1):1994;37-44
14. Tanaka F., Abe M., Akiyoshi T., Nomura T., Sugimachi K., Kishimoto T., et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the interleukin-6 gene using adenovirus vector. Cancer Res. 57:1997;1335-1343
15. Flannery C.R., Little C.B., Hughes C.E., Curtis C.L., Caterson B., Jones S.A. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol. 19:2000;549-553
16. Isshiki H., Akira S., Sugita T., Nishio Y., Hashimoto S., Pawlowski T., et al. Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. New Biol. 3:1991;63-70
17. Kluger M.J., Kozak W., Leon L.R., Conn C.A. The use of knockout mice to understand the role of cytokines in fever. Clin Exp Pharmacol Physiol. 25:1998;141-144
18. Navarra P., Tsagarakis S., Faria M.S., Rees L.H., Besser G.M., Grossman A.B. Interleukin-1 and -6 stimulate the release of corticotrophin realising hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology. 128:1990;37-44
19. Mastorakos G., Ilias I. Relationship between interleukin-6 (IL-6) and hypothalamic-pituitary-adrenal axis hormones in rheumatoid arthritis. Zeitschrift fur Rheumatologie. 59(Suppl 2):2000;75-79
20. Cutolo M., Giusti M., Foppiani L., Seriolo B., Briata M., Bisso A., et al. The hypothalamic-pituitary-adrenocortical and gonadal axis function in rheumatoid arthritis. Zeitschrift fur Rheumatologie. 59(Suppl 2):2000;II/65-II/69
21. Katsume A., Miyai T., Suzuki H., Moriguchi Y., Kawata H., Tatsumi T., et al. Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol. 82:1997;117-124
22. Sui X., Tsuji K., Ebihara Y., Tanaka R., Muraoka K., Yoshida M., et al. Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. Blood. 93:1999;2525-2532
23. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 182:1995;1461-1468
24. Brozik M., Rosztoczy I., Meretey K., Balint G., Gaal M., Balogh Z., et al. Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol. 19:1992;63-68
25. Boe A., Baiocchi M., Carbonatto M., Papoian R., Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Eur Cytokine Netw. 11:1999;1057-1064
26. Uson J., Balsa A., Pascual-Salcedo D., Cabezas J.A., Gonzalez-Tarrio J.M., Martin-Mola E., et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol. 24:1997;2069-2075
27. Swaak A.J., van Rooyen A., Nieuwenhuis E., Aarden L.A. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol. 17:1988;469-474
28. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun. 5(Suppl A):1992;123-132
29. Guerne P.A., Zuraw B.L., Vaughan J.H., Carson D.A., Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 83:1989;585-592
30. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., et al. Excessive production of interleukin-6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 18:1988;1797-1801
31. Dasgupta B., Corkill M., Kirkham B., Gibson T., Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 19:1992;22-25
32. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 11:1996;88-95
33. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41:1998;2117-2121
34. Mihara M., Kotoh M., Nishimoto N., Oda Y., Kumagai E., Takagi N., et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol. 98:2001;319-326
35. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 20:1993;259-262
36. Kavanaugh A.F., Schulze-Koops H., Davis L.S., Lipsky P.E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule-1 monoclonal antibody. Arthritis Rheum. 40:1997;849-853
37. Winter G., Milstein C. Man-made antibodies. Nature. 349:1991;293-299
38. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46:2002;3143-3150
39. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324
40. van Gestel A.M., Prevoo M.L., van 't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39:1996;34-40
41. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:1995;727-735
42. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Takeuchi T., Hashimoto F., et al. A multi-center, randomized, double-blind, placebo-controlled trial of humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody (MRA) in rheumatoid arthritis. Arthritis Rheum. 46(Suppl):2002;S559
43. Nishimoto N., Nakahara K., Kishimoto T. Anti-interleukin-6 receptor antibody therapy normalizes serum vascular endotherial growth factor (VEGF) in patients with rheumatoid arthritis (RA). Arthritis Rheum. 46(Suppl):2002;S250
44. Maini R. Charisma Study Group A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 62(Suppl):2003;64
45. Iwamoto M., Nara H., Hirata D., Minota S., Nishimoto N., Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 46:2002;3388-3389